Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M

Kiniksa Pharmaceuticals International, plc

2022-Q3 EPS reported -$1.78 revenue$19,799,000

ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.
Net loss of $30.5M improved from $43.8M in Q3 2020; operating expenses $42.8M.
Cash and investments $200.2M, no debt; cash expected to fund operations into 2023.
Mavrilimumab Phase 3 in COVID-19 ARDS data expected Q1 2022; vixarelimab Phase 2b data in prurigo nodularis expected 2H 2022.
Over 200 physicians prescribed ARCALYST for recurrent pericarditis since approval; >190M lives covered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.